Supplementary

Table S1. **List of primers used for TP53 amplification and M13/P1 primers**

Primer Name	Sequence
TP53ex2_F	GATCCCCACTTTTCCTCTTG
TP53ex2_R	CTTCCCACAGGTCTCTGCTA
TP53ex3_F	ACTGACTTTCTGCTCTTGTCTT
TP53ex3_R	GGACTGTAGATGGGTGAAAA
TP53ex4a_F	TGCTCTTTTCACCCATCTAC
TP53ex4a_R	AGGGACAGAAGATGACAGG
TP53ex4b_F	CACCAGCAGCTCCTACAC
TP53ex4b_R	GCATTGAAGTCTCATGGAAG
TP53ex5start_F	AGTTGCTTTATCTGTTCACTTGT
TP53ex5start_R	GTGCTGTGACTGCTTGTAGAT
TP53ex6_F	GATTCCTCACTGATTGCTCTT
TP53ex6_R	CACTGACAACCACCCTTAAC
TP53ex9_F	TTATGCCTCAGATTCACTTTTAT
TP53ex9_R	TTTGAGTGTTAGACTGGAAACTT
TP53ex10_F	ATATACTTACTTCTCCCCCTCCT
TP53ex10_R	GATGAGAATGGAATCCTATGG
TP53ex11_F	CACTCATGTGATGTCATCTCTC
TP53ex11_R	GGGAACAAGAAGTGGAGAA
TP53ex5_F	CAGCTGTGGGTTGATTCC
TP53ex5_R	AGACCTAAGAGCAATCAGTGAG
TP53ex7_F	ATCTTGGGCCTGTGTTATC
TP53ex7_R	GGTCAGAGGCAAGCAGAG
TP53ex8_F	TTGCTTCTCTTTTCCTATCCT
TP53ex8_R	ATAACTGCACCCTTGGTCTC
M13	TGTAAAACGACGGCCAGT
P1	CCTCTCTATGGGCAGTCG

Table S2. **List of primers designed to target patient specific TP53 mutation**

| Primer Name	Sequence
TP53_266to82_F	CCTGAGTAGTGGTAATCTACTGG
TP53_266to82_R	GAGATTCTCTTCCTCTGTGC
TP53209_13_F	AGTTGCAAACCAGACCTCAG
TP53209_13_R	GAAATTTGCGTGTGGAGTAT
TP53_ex8end_F	CGCTTCTTGTCCTGCTTG
TP53_ex8end_R	GAGAATCTCCGCAAGAAAG
TP53_R175H_F	GCCATCTACAAGCAGTCACA
TP53_R175H_R	CTGCTCACCATCGCTATCTG
TP53ex5spl4_F	GACTTTCAACTCTGTCTCCTTC
TP53ex5a_R	TGTGGAATCAACCCACAG
TP53_242to41F	ACAACTACATGTGTAACAGTTCC
TP53_242to41R	CCAGTGTGATGATGGTGAGG
TP53_158_F	GTGCTGTGACTGCTTGTAGAT
TP53_158_R	CAGCTGTGGGTTGATTCC
TP53_35_F	CTCTTTTCACCCATCTACAGTC
TP53_35_R	ACAGCATCAAATCATCCATT
TP53_ex8end_F	CGCTTCTTGTCCTGCTTG
TP53_ex8end_R	GAGAATCTCCGCAAGAAAG
TP53_195_F	ATTCCTCACTGATTGCTCTTAG
TP53_195_R	AAGTGTTTCTGTCATCCAAATAC
TP53_242F	ACAACTACATGTGTAACAGTTCCT
TP53_257R	CTCCTGACCTGGAGTCTTC
TP53_224F	ACTTTTCGACATAGTGTGGTG
TP53_224R	CTGACAACCACCCTTAACC
TP53_237_F	CTGGAGTCTTCCAGTGTGAT
TP53_237_R	GTACCACCATCCACTACAACT

Figure S1. Survival outcomes stratified by the presence of TP53 mutation in tumor DNA. Kaplan Meier survival estimates of overall survival (A) and disease free survival (B) of the entire cohort (N=70) demonstrating no difference in clinical outcomes based on the presence of TP53 mutations.